Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q15024
UPID:
EXOS7_HUMAN
Alternative names:
Exosome component 7; Ribosomal RNA-processing protein 42; p8
Alternative UPACC:
Q15024; Q96E72
Background:
Exosome complex component RRP42, also known as Exosome component 7 and Ribosomal RNA-processing protein 42, plays a crucial role in RNA metabolism. It is a non-catalytic component of the RNA exosome complex, involved in the degradation and processing of various RNA species. This includes the maturation of stable RNA species like rRNA, snRNA, and snoRNA, as well as the elimination of RNA processing by-products and non-coding transcripts. Its function extends to the cytoplasm where it is pivotal in mRNA turnover and the degradation of unstable mRNAs.
Therapeutic significance:
Understanding the role of Exosome complex component RRP42 could open doors to potential therapeutic strategies.